← Eichor
Condition: Hr Her2 Negative Breast Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Hr Her2 Negative Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 · 40 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06625775Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT06176534Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Phase 1 · 29 location(s) · Novartis Pharmaceuticals · NCT06562192Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer
Phase 2 · 1 location(s) · Yonsei University · NCT06837792Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06705127Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index
Phase 2 · 1 location(s) · Shantou Central Hospital · NCT05728268Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Canc
Phase 2 · 1 location(s) · RemeGen Co., Ltd. · NCT06642545Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT07492394Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
Phase 1 · 1 location(s) · Novartis Pharmaceuticals · NCT07630961DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients
Phase N/A · 1 location(s) · Mayo Clinic · NCT06388122Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Br
Phase 1/Phase 2 · 3 location(s) · Washington University School of Medicine · NCT06374459Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
Phase 2 · 1 location(s) · Brown University · NCT06974604PRE-I-SPY Phase I/Ib Oncology Platform Program
Phase 1 · 7 location(s) · QuantumLeap Healthcare Collaborative · NCT05868226A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Phase 1 · 4 location(s) · Cogent Biosciences, Inc. · NCT07383506Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Recepto
Phase N/A · 40 location(s) · Novartis Pharmaceuticals · NCT06930859Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2
Phase N/A · 1 location(s) · University Hospital, Basel, Switzerland · NCT07546695A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Phase 2 · 13 location(s) · Processa Pharmaceuticals · NCT06568692The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT05075512Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer
Phase 2 · 2 location(s) · Xijing Hospital · NCT06914440Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer
Phase 1/Phase 2 · 1 location(s) · Nagoya City University · NCT07164976Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06341894BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Phase 1 · 63 location(s) · BeOne Medicines · NCT06120283Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
Phase 3 · 203 location(s) · Celcuity Inc · NCT06757634Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07258108Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer
Phase N/A · 1 location(s) · University Hospital Tuebingen · NCT05878314A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Ad
Phase 1 · 15 location(s) · TerSera Therapeutics LLC · NCT07310420ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Soli
Phase 1/Phase 2 · 15 location(s) · Avenzo Therapeutics, Inc. · NCT06998407Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced
Phase 2 · 2 location(s) · wanghaibo · NCT07285382Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and
Phase 2 · 1 location(s) · Shengjing Hospital · NCT05638594
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.